Influence of molecular properties on oral bioavailability of lipophilic drugs Mapping of bulkiness and different measures of polarity

Pharmaceutical Development and Technology

Volumn 14, Issue 3, 2009, Pages 312-320

  Kuentz, Martin Thomas ^a   Arnold, Yvonne ^a  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Bioavailability; HLB; Lipophilic drugs; Molecular modeling; Polarity; Solubility parameter

Indexed keywords

ALMITRINE; ALPRAZOLAM; ANASTROZOLE; APREPITANT; ARTEMETHER; BETAMETHASONE; BROTIZOLAM; CALCITRIOL; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOMETHIAZOLE; CLOZAPINE; DESOGESTREL; ERLOTINIB; ETHINYLESTRADIOL; ETONOGESTREL; EXEMESTANE; FELODIPINE; FENFLUMIZOLE; FINASTERIDE; FLUOCORTOLONE; FLUORESCEIN; FLUPENTIXOL; FLUPIRTINE; GEFITINIB; GESTODENE; GRISEOFULVIN; KYNOSTATIN 272; NORDAZEPAM; UNINDEXED DRUG; VALPROMIDE; DRUG; LIPID;

ARTICLE; DRUG BIOAVAILABILITY; LIPOPHILICITY; MOLECULAR MODEL; MOLECULAR WEIGHT; ORAL DRUG ADMINISTRATION; POLARIZATION; PREDICTION; PRIORITY JOURNAL; SOLUBILITY; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMICAL MODEL; CHEMISTRY; HUMAN;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; HUMANS; LIPIDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 70149118117     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802626296     Document Type: Article

References (46)

1. Cuatrecasas P. Drug discovery in jeopardy. J Clin Investig. 2006;116(11):2837-2842.
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc. 2004;3(8):711-715.
3. Wang J, Urban L. The impact of early ADME profiling on drug discovery and development strategy. Drug Disc. 2004;4:73-86.
4. Van de Waterbeemd H, Gifford E. ADMET in silico modeling: Towards prediction paradise? Nature Rev. 2003;2(3):192-204.
5. Lombardo F, Gifford E, Shalaeva MY. In Silico ADME prediction: Data, models, facts, myths. Mini Rev Medicinal Chem. 2003;3(8):861-875.
6. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubiliy and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1-3):3-25.
7. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledgebased approach in designing combinatorial or medicinal discovery libraries for drug discovery. J Comb Chem. 1999;1:55-68.
8. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615-2623.
9. Biswas D, Roy S, Sen S. A simple approach indexing the oral druglikeness of a compound: Discriminating druglike compounds from nondruglike ones. J Chem Model. 2006;46:1394-1401.
10. Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship. Pharmaceut Res. 2000;17(6):639-644.
11. Yoshida F, Topliss JG. QSAR model for drug human oral bioavailability. J Medicinal Chem. 2000;43(13):2575-2585.
12. Perez MAC, Sanz MB, Torres LR, Avalos RG, Gonzalez MP, Diaz HG. A topological sub-structural approach for predicting human intestinal absorption of drugs. Eur J Medicinal Chem. 2004;39(11):905-916.
13. Deconinck E, Xu QS, Put R, Coomans D, Massart DL, Vander Heyden Y. Prediction of gastro-intestinal absorption using multivariate adaptive regression splines. J Pharmaceut Biomed Anal. 2005;39(5):1021-1030.
14. Deconinck E, Ates H, Callebaut N, Van Gyseghem E, Vander Heyden Y. Evaluation of chromatographic descriptors for the prediction of gastro-intestinal absorption of drugs. J Chromatogr A. 2007;1138(1-2):190-202.
15. Kuentz M, Wyttenbach N, Kuhlmann O. Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations - evaluation of quantitative excipient effects. Pharm Dev Technol. 2007;12:275-283.
16. Yu L, Crison J, Amidon G. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm. 1996:171(2):157-163.
17. Yu L, Amidon G. Characterisation of small intestinal transit time distribution in humans. Int J Pharm. 1998;171(2):157-163.
18. Yu L, Amidon G. Saturable small intestinal drug absorption in humans: Modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm. 1998;45(2):199-203.
19. Agoram B, Woltosz W, Bolger M. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(S1):S41-67.
20. Willmann S, Schmitt W, Keldenich J, Dressman J. A physiological model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 2003;20(11):1766-1771.
21. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman J. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem. 2004;47(16):4022-4031.
22. Willmann S, Ediginton AN, Dressman J. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm Res. 2007;24(7):1275-1282.
23. Parrott N, Lavé Th. Prediction of intestinal absorption: Comparative assessment of GastroPlusTM and IDEATM. Eur J Pharm Sci. 2002;17:51-61.
24. Parrott N, Jones H, Paquereau , Lavé Th. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol. 2005;96:193-199.
25. Kuentz M, Nick S, Parrott N, Roethlisberger D. A strategy for preclinical formulation development using GastroPlusTM as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci. 2006;27(1):91-99.
26. Turner JV, Glass BD, Agatonovic-Kustrin S. Prediction of drug bioavailability based on the molecular structure. Analyt Chimica Acta. 2003;485:89-102.
27. Turner JV, Maddalena DJ, Agatonovic-Kustrin S. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm Res 2004;21(1):68-82.
28. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery.
29. Prediction of oral absorption by correlation and classification. J Chem Info Modeling. 2007;47(1):208-218.
30. Hou T, Wang J, Li Y. ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. J Chem Info Modeling. 2007;47(6):2408-2415. (Pubitemid 350275105)
31. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J Chem Info Modeling. 2007;47(2):460-463.
32. Lipinski Ch. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacolog Toxicolog Meth. 2000;44:235-249.
33. Fedors RF. Method for estimating both the solubility parameters and molar volumes of liquids. Addendum. Polymer Engineer Sci. 1974;14(6):472.
34. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714-3717.
35. Tetko I, Poda GI. Prediction of logP with property-based methods. Meth Princ Medicinal Chem 2008;37(Molec Drug Prop).:381-406.
36. Van Krevelen DW. Properties of polymers: Their correlation with chemical structure; their numerical estimation and prediction from additive group contributions. Amsterdam, The Netherlands: Elsevier; 1997:898
37. Hartmann T, Schmitt J. Lipophilicity - beyond octanol/water: A short comparison of modern technologies. Drug Disc Today: Technol. 2004;1(4):431-439.
38. Dressman J, Amidon G, Fleisher D. Absorption potential. Estimation of the fraction absorbed for orally administered compounds. J Pharm Sci. 1985;74(5):588-589.
39. Boxenbaum H. Absorption potential and its variants. Pharm Res. 1999;16(12):1893.
40. Yalkovsky SH. Techniques of solubilisation of drugs. New York, Basel: Marcel Dekker; 1981.
41. Yang G, Ran Y, Yalkovsky SH. Prediction of the aqueous solubility: Comparison of the general solubility equation and the method using an amended solvation energy relationship. J Pharm Sci. 2002;92(2):517-533
42. Martin AN. Solubility and distribution phenomena in physical pharmacy. Philadelphia, London: Lea Febiger; 1999: 212-250.
43. Gruenbauer HJ, Tomlinson E. Local composition models in pharmaceutical chemistry. I. Liquid-liquid distribution coef- ficients from COMMON UNIQUAC parameters. Int J Pharm. 1984;21(1):61-74.
44. Hou T, Wang J, Zhang W, Wang W, Xu X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem. 2006;13:2653-2667.
45. Lindahl A, Persson B, Ungell AL, Lennernäs H. Surface activity and concentration dependent intestinal permeability in the rat. Pharm Res. 1999;16(1):97-102.
46. Lu J, Crimin K, Goodwin J, Crivori P, Orrenius C, Xing L, Tandler P, Vidmar J, Amore B, Wilson A, Stouten P, Burton P. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem. 2004;47(24):6104-6107.